Jamaica Szeliga is a Partner in the Intellectual Property group. With more than 20 years of experience, Ms. Szeliga prosecutes, manages, and oversees global patent portfolios as well as litigating patent and trade secret matters and providing counseling, opinion, and IP transactional services. Her clients range from international conglomerates to first-time inventors.
A registered Patent Attorney, Ms. Szeliga prosecutes patent applications in both the U.S. and abroad in a variety of technology areas. One focus is in biotechnology, pharmaceuticals, and other health-related industries, where Ms. Szeliga has pursued patents for clients relating to, e.g., gene editing, antibody therapies, digital health, medical devices and diagnostics, and supplements. Other key areas include consumer goods and fashion, with Ms. Szeliga prosecuting both utility and design patents in those fields.
As part of her practice, Ms. Szeliga also performs comprehensive IP audits, which evaluate how a company identifies patentable inventions and trade secrets and how those assets are protected. She advises on maximizing invention “capture,” improving patent strategy, strengthening trade secret controls, and also trains and coaches employees on IP issues.
Ms. Szeliga regularly provides freedom-to-operate and invalidity assessments, and drafts IP-related contracts and contract provisions such as those relating to licensing, co-development, confidentiality, and mergers and acquisitions. She further is an accomplished litigator with experience in patent litigation (both for utility and design patents) and trade secret litigation. A former clerk at the United States Court of Appeals for the Federal Circuit, she has led cases in district courts, in multi-district litigation, before the PTAB (IPRs and PGRs), and in TTAB oppositions, and has argued before the Federal Circuit and the Fourth Circuit.
Representative Experience
- Oversight of global patent prosecution and management of more than 150 applications for a gene editing company.
- Act as “outside” in-house IP counsel for certain clients, including prosecuting patents, reviewing and approving public disclosures, drafting IP contracts, overseeing trademark challenges, and assisting in the realization, protection, and commercialization of IP.
- Lead counsel in trade secret and breach of contract litigation matter relating to genetic databases.
- Lead counsel in four inter partes review (IPR) and one post grant review (PGR) proceedings, successfully challenging beverage company claims to sweet tea.
- Provided IP due diligence review for reps and warranties insurers on more than 120 mergers, acquisitions, and asset sales.
- Patent litigation counsel in matters involving medical devices, biologics, textiles, fashion and accessories, toys, and various mechanical products, including cases both pursuing and defending against design patent infringement claims.
- Representation of both pharmaceutical and generic companies in Hatch-Waxman patent litigation and advising companies on the Biologics Price Competition and Innovation Act.
Honors & Awards
- “Top 50 Women Leaders in Law of 2023,” Women We Admire
- “Top 50 Women Leaders in Law of 2022,” Women We Admire
- Washington, DC Super Lawyers “Rising Stars,” Intellectual Property Litigation (Thomson Reuters) (2016-2017)
Publications and Speeches
- "Health Care Beat Episode 42: 2023 Health Law Year-In-Review," Co-Speaker, Podcast, Seyfarth Shaw LLP (February 1, 2024)
- "Health Care Beat Episode 41 – Insuring Success: The Utilization of Insurance in Health Care M&A Transactions," Co-Speaker, Podcast, Seyfarth Shaw LLP (August 30, 2023)
- "Health Care Beat Episode 40: US Digital Health Series – Payment & Reimbursement," Co-Speaker, Podcast, Seyfarth Shaw LLP (August 3, 2023)
- "Health Care Beat Episode 39: US Digital Health Series – Advertising, Marketing, and E-Commerce," Co-Presenter, Podcast, Seyfarth Shaw LLP (June 30, 2023)
- "Health Care Beat Episode 38: US Digital Health Series – Data Protection and Management," Co-Speaker, Podcast, Seyfarth Shaw LLP (June 1, 2023)
- "Health Care Beat Episode 37: Labor Relations in Health Care – What to Expect at the Bargaining Table and From the NLRB in 2023," Co-Speaker, Podcast, Seyfarth Shaw LLP (May 16, 2023)
- "Health Care Beat Episode 36: US Digital Health Series – Transactional Issues," Co-Presenter, Podcast, Seyfarth Shaw LLP (April 26, 2023)
- Health Care Beat Episode 35: US Digital Health Series – Intellectual Property," Co-Speaker, Podcast, Seyfarth Shaw LLP (April 4, 2023)
- Co-presenter on US IP Law to delegation of IP professionals from Bosnia and Herzegovina at the request of the Department of Commerce (March 2023).
- “Overview of Digital Health in the United States," Co-Author, Lexology Getting the Deal Through (February 8, 2023)
- Overview of Digital Health in the United States," Co-Author, Lexology Getting the Deal Through (February 24, 2022)
- "Seyfarth Shaw IP Team Files Supreme Court Amici Brief in Trade Dress Case," Co-Author, Legal Update, Seyfarth Shaw LLP (October 28, 2021)
- Health Care Beat Podcast: Episode 12: COVID-19 Vaccines Are Here: Now What?, Speaker, Seyfarth Shaw LLP (August 5, 2021)
- “A Third Option: Limited IP Waiver Could Solve Our Pandemic Vaccine Problems," Co-Author, IPWatchdog (July 21, 2021) · "FDA Issues Emergency Use Authorization for COVID-19 Vaccine," Co-Author, Legal Update, Seyfarth Shaw LLP (December 14, 2020)
- "FDA Approves Veklury (remdesivir) As The First Treatment For COVID-19," Co-Author, Legal Update, Seyfarth Shaw LLP (October 26, 2020)
- "Chinese Manufacturers of Personal Protective Equipment Gave False U.S. Agent Information to Food and Drug Administration," Co-Author, Legal Update, Seyfarth Shaw LLP (June 24, 2020)
- "FDA Revokes Emergency Use Authorization For Highly Watched Chloroquine and Hydroxychloroquine - But They Can Still Be Prescribed," Co-Author, Legal Update, Seyfarth Shaw LLP (June 18, 2020)
- "FDA Revises Guidance on Face Masks, Respirators, and Face Shields to Address Covid-19 Concerns," Co-Author, Legal Update, Seyfarth Shaw LLP (May 29, 2020)
- "FDA Updates Emergency Use Authorization For Chinese Respirators," Co-Author, Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- Small and Micro Businesses Alert: USPTO Announces Program for Applications Covering Prevention and Treatment of COVID-19," Co-Author, Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- "FDA Collection and Labeling Protocols For Use of Convalescent Plasma As A Treatment for COVID-19," Co-Author, Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- "FDA Provides Safety Communication Relating to Use of Antimalarial Drugs Hydroxychloroquine and Chloroquine In the Treatment of COVID-19," Co-Author, Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- "FDA Provides Guidance on How to Request Authorization to Use Convalescent Plasma as a Treatment for COVID-19," Co-Author, Legal Update, Seyfarth Shaw LLP (April 27, 2020)
- "FDA Authorizes Synthetic Nasal Swab to Increase COVID-19 Testing," Co-Author, Legal Update, Seyfarth Shaw LLP (April 22, 2020)
- "Guide For General Public: FDA Explains How Everyone Can “Make a Difference” During COVID-19 With Simple Infographic, Update," Co-Author, Legal Update, Seyfarth Shaw LLP (April 21, 2020)
- "FDA and NCI to Review COVID-19 Antibody Tests Marketed Under FDA Guidance Permitting Sale Without FDA Authorization," Co-Author, Legal Update, Seyfarth Shaw LLP (April 17, 2020)
- "Head to Toe: Summary of FDA COVID-19 Guidance Relating to Gowns, Other Apparel, and Gloves," Co-Author, Legal Update, Seyfarth Shaw LLP (April 13, 2020)
- "FDA Announces the Creation of CTAP—Coronavirus Treatment Acceleration Program—to Assist Drug Developers and Evaluators," Co-Author, Legal Update, Seyfarth Shaw LLP (April 10, 2020)
- "FDA Issues Updated Guidance Relating to its Enforcement Policy for Face Masks and Respirators," Legal Update, Co-Author, Seyfarth Shaw LLP (April 8, 2020)
- "CDC Provides Recommendations for Respirators When N95 Respirators Are Not Available in COVID-19 Crisis," Co-Author, Legal Update, Seyfarth Shaw LLP (April 7, 2020)
- "FDA Issues Guidance Documents Directed to Blood Donations as Part of COVID-19 Public Health Emergency Measures," Co-Author, Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- "FDA Issues Guidance Regarding Alcohol-Based Hand Sanitizers For COVID-19 Prevention," Co-Author, Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- "USPTO Extends Certain Patent-Related Timing Deadlines," Co-Author, Legal Update, Seyfarth Shaw LLP (April 3, 2020) · "FDA Emergency Use Authorizations ('EUA') for COVID-19: What is an EUA and What is Currently Covered?," Co-Author, Legal Update, Seyfarth Shaw LLP (April 2, 2020)
- "FDA Eases Enforcement to Expand Remote Care of Pets and Food-Producing Animals," Co-Author, Legal Update, Seyfarth Shaw LLP (April 1, 2020)
- "FDA Eases Enforcement to Help Make More Ventilators Available," Co-Author, Legal Update, Seyfarth Shaw LLP (March 27, 2020)
- "False Advertising: Changing Your Business To Meet Market Needs During The COVID-19 Pandemic," Co-Author, Legal Update, Seyfarth Shaw LLP (March 25, 2020)
- "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Trademark Applicants and Trademark Owners," Co-Author, Legal Update, Seyfarth Shaw LLP (March 21, 2020)
- "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Patent Applicants and Patent Owners," Co-Author, Legal Update, Seyfarth Shaw LLP (March 20, 2020)
- "Sandoz v. Amgen: The Latest in Biosimilar ‘Dances’," BioLoquitur, Seyfarth Shaw LLP (June 28, 2017)
- "Sandoz v. Amgen: Supreme Court Nixes Post-Approval Waiting Period for Biosimilars," Client Alert, Seyfarth Shaw LLP (June 15, 2017)
- "High Court Limits Where Patent Suits Can Be Filed," One Minute Memo, Seyfarth Shaw LLP (May 31, 2017)
- "Venue in ANDA Litigation: Will TC Heartland Be a Sea Change or Just a Drop in the Bucket?," BioLoquitur, Seyfarth Shaw LLP (May 26, 2017)
- "Trends in Paragraph IV Challenges: What Lies Ahead in 2017 and Beyond," presented by The Knowledge Group (May 24, 2017) · "Legislative Overview: First Quarter 2017,” BioLoquitur, Seyfarth Shaw LLP (April 14, 2017)
- "The BPCIA Patent Dance - What Biosimilar Companies Need to Know," presented by The Knowledge Group (January 10, 2017)
- "USPTO’s Proposed Changes to AIA Post-Grant Amendment Proceedings: Preparing for the Big Shift," presented by The Knowledge Group (March 29, 2016)
Memberships and Affiliations
- American Bar Association, Member
- The Federal Circuit Bar Association, Member
- The American Chemical Society, Member
- The Washington Area Lawyers for the Arts, Member
News, Events & Insights
Education
Harvard Law School, J.D.
- Magna cum laude
Stanford University, B.S. Chemistry with Biology Minor
- With Distinction (top 10%)
Previous Experience
- Seyfarth Shaw, Partner
- Leydig, Voit & Mayer, Shareholder
- Wilmer Hale, Counsel
Areas of Practice
Admissions
- District of Columbia
- New York
- U.S. Patent and Trademark Office - Registered Patent Attorney
- U.S. Supreme Court
- U.S. Court of Appeals for the 4th Circuit
- U.S. Court of Appeals for the Federal Circuit
- D.C. Court of Appeals